Compare JVA & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JVA | LSTA |
|---|---|---|
| Founded | 1971 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Misc Health and Biotechnology Services |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.0M | 20.9M |
| IPO Year | 2005 | N/A |
| Metric | JVA | LSTA |
|---|---|---|
| Price | $3.72 | $2.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $23.50 |
| AVG Volume (30 Days) | 41.4K | ★ 139.2K |
| Earning Date | 09-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 64.91 | N/A |
| EPS | ★ 0.32 | N/A |
| Revenue | ★ $89,748,681.00 | $1,070,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.45 | ★ N/A |
| Revenue Growth | ★ 17.92 | N/A |
| 52 Week Low | $2.75 | $1.81 |
| 52 Week High | $9.93 | $4.20 |
| Indicator | JVA | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 42.48 | 40.79 |
| Support Level | $3.32 | $1.86 |
| Resistance Level | $3.84 | $2.13 |
| Average True Range (ATR) | 0.25 | 0.16 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 45.18 | 53.76 |
Coffee Holding Co Inc is engaged in wholesale coffee operations, including manufacturing, roasting, packaging, marketing, and distributing roasted and blended coffees for privately labeled accounts and its brands, and it sells green coffee. The Company also manufactures and sells coffee roasters. Its products include wholesale green coffee, private-label coffee, and branded coffee. The company sells its coffee products throughout the United States, Canada, and certain Asian countries. The group's services are Custom Blending, Food Service Programs, and Private Label Services.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.